#USA #New York #Rare Diseases #Precision AQ #Julia Wermerskirchen

Precision AQ Expands Access Experience Team to Tackle Evolving Challenges in Rare Diseases

Precision AQ, a key player in life sciences commercialization, recently announced a significant expansion to its Access Experience Team (AET), aimed at addressing the mounting patient access challenges associated with rare diseases. The decision comes in response to the rapid evolution of market dynamics and the growing demand for access to innovative therapies that are critical for patient well-being.

The notable addition to the team is Dr. Julia Wermerskirchen, PharmD, who joins Precision AQ with a distinguished track record in payer negotiations and reimbursement strategies specific to rare and orphan diseases. Wermerskirchen's vast experience—spanning over 15 years in managed care and specialty pharmacy—positions her as an expert in navigating the complex landscape of patient access to high-cost therapies. Her background includes co-founding Optum Frontier Therapies, where she was instrumental in advancing access initiatives for rare disease treatments.

As the landscape for rare disease therapies becomes increasingly competitive, with more than half of FDA-approved novel therapies in 2024 targeting rare conditions, Precision AQ recognizes the need for a robust approach to market access strategies. The addition of Wermerskirchen significantly strengthens the AET’s capabilities in dealing with the heightened scrutiny from payers and the stringent reimbursement policies that have emerged in this rapidly changing environment.

“Julia’s expertise is critical to reinforcing our commitment to enhance access to transformative therapies for patients,